Nelson Advisors: Apple acquires Sonera under the radar to build new sensing capabilities into its hardware

Nelson Advisors

21 minutes ago

11 min read

Nelson Advisors: Apple acquires Sonera under the radar to build new sensing capabilities into its hardware

Apple Just Bought a Company That Can Read Your Brain's Magnetic Signals, Quietly

There was no keynote, no press release, no carefully art-directed product shot. Apple's latest acquisition surfaced the way most of its acquisitions do: through a regulatory filing nobody was supposed to notice.

Buried in the European Union's database of mergers likely to be significant in the region, a single entry revealed that Apple had acquired Sonera, a Berkeley born startup that builds non-invasive sensors capable of reading neural signals straight from the brain and body.

The deal reportedly closed in May 2026. Apple has said nothing about it publicly. Sonera's own website has quietly gone dark. And yet this may turn out to be one of the more consequential acquisitions in Apple's recent history, because it points toward a future in which your Apple Watch, or whatever comes after it, doesn't just track your heart rate. It reads your muscles, and possibly your thoughts.

Who Is Sonera, and What Does It Actually Make?

Sonera was founded in 2018 by Nishita Deka and Dominic Labanowski, two UC Berkeley students who set out to solve a problem that has quietly limited the entire field of brain-computer interfaces: the tools for reading neural activity are either too invasive, too expensive, or too imprecise for everyday use. Operating for years under the name Sonera Magnetics, the company stayed in stealth mode until September 2023, when it emerged with $20 million in funding, an $11 million seed round led by Amplify Partners, with participation from Abstract Ventures, Spark Capital, Material Impact and Boom Capital. Notably, one of its angel investors was Josh Duyan, a co-founder and former chief science officer at CTRL-Labs, the neural-interface company Facebook (now Meta) acquired in 2019 for a reported $500 million to $1 billion. That pedigree matters: CTRL-Labs' wristband technology, which reads electrical signals from motor neurons to translate intention into digital input, is one of the most cited precedents for exactly the kind of consumer neural interface Sonera has been chasing, except Sonera took a different physical approach to get there.

Where most neural sensing technology, EEG caps, EMG electrodes, the surface sensors used in research labs and in products like CTRL-Labs' band, relies on detecting the electrical activity generated by nerves and muscles, Sonera built its technology around magnetic fields instead. As co-founder Nishita Deka put it when the company came out of stealth, the goal was "to detect brain activity using cheaper, faster methods that are still high-performance." Every electrical signal in the body, including the ones firing between neurons and the ones activating your muscles, generates a tiny corresponding magnetic field. Traditional brain-imaging techniques that read these magnetic fields, such as magnetoencephalography (MEG), have existed for decades, but they typically require room-sized machines, magnetically shielded chambers, and equipment that costs millions of dollars. Sonera's pitch was that it could shrink that capability down into something closer to chip scale.

The advantage of the magnetic approach over electrical sensing is a genuinely interesting piece of physics. Electrical signals get distorted and dampened as they pass through the skull, skin, hair, and other tissue, which is why EEG readings are famously noisy and why electrode-based sensors typically need direct, often gel-assisted, contact with the skin to get a clean signal. Magnetic fields, by contrast, pass through tissue and even through clothing with far less distortion. That means a magnetic sensor can, in principle, sit near the body rather than directly on it, and still pick up a higher-fidelity signal than an electrical sensor pressed right up against the skin. It's the difference between trying to hear a conversation through a wall versus feeling the vibration of it and Sonera built its business on the bet that the vibration-based approach could eventually be made cheap enough, and small enough, to live inside a consumer gadget.

The S1 Chip

Sonera's first commercial product, and the clearest signal of where the company was headed before Apple came calling, was the S1 chip. Despite the company's original framing around brain activity, the S1's initial application target was muscle sensing rather than direct brain reading, arguably the more tractable, nearer-term problem, since muscle signals are stronger and easier to isolate than the faint magnetic traces produced by neurons deep in the brain. According to Sonera's own materials, the S1 works by measuring the magnetic fields generated by the electrical currents produced during neural and muscular activity, without requiring the sensor to touch the skin directly. That is a meaningfully different proposition from today's optical heart-rate sensors or electrical EMG patches, which generally need skin contact to function well.

Sonera positioned the S1 as a foundation technology rather than a single-purpose gadget, and the company talked about several concrete use cases: control of advanced prosthetic limbs, continuous monitoring of neuromuscular conditions such as ALS, muscular dystrophy, or Parkinson's-related tremor, biomarker discovery for neurological and muscular disease research, and sports and fitness performance tracking based on real muscle activation patterns rather than proxies like heart rate or accelerometer data. And crucially, in its own words, the company described the S1 as capable of enabling "an entirely new class of consumer wearables and experiences based on muscle activity", a line that, in hindsight, reads almost like a pitch deck slide aimed squarely at a company like Apple.

Beyond muscle sensing, Sonera also described its underlying platform as capable of registering brain magnetic activity directly, and suggested the technology could eventually support "thought control" of devices — using detected neural signals as an input method, similar in spirit to what Neuralink is pursuing with implanted electrodes, or what Meta has explored with the wristband technology it inherited from CTRL-Labs, but without surgery and without needing the device to sit on bare skin. That's a much longer-term and technically harder target than muscle sensing, and there is no public evidence yet that Sonera had a working consumer-grade product for brain-signal decoding rather than muscle-signal decoding. But it was clearly the company's north star, and it's a large part of why an acquisition by Apple looks significant rather than incidental.

How the Deal Came to Light

Apple has a long-standing habit of acquiring small companies quietly and saying almost nothing about it, a practice that dates back years and has been true of dozens of deals, from Beddit, the sleep-tracking company Apple bought in 2017, to various AI, chip, and camera-technology startups absorbed with barely a public trace. Apple's standard line when asked about acquisitions, repeated by executives for over a decade, is that the company "buys smaller companies from time to time" and generally doesn't discuss its purpose or plans. Sonera appears to be following that exact playbook: no announcement, no confirmation, and by the time the deal became visible, Sonera's website had already been taken offline, scrubbing the public record of the company's own description of its technology.

What forced this deal into daylight wasn't a leak or an SEC filing, it was European regulation. The European Union maintains a public database tracking mergers and acquisitions that could be significant enough to warrant regulatory scrutiny within its jurisdiction, part of its broader push for transparency around large companies' acquisition activity, particularly under scrutiny tied to the Digital Markets Act, which designates Apple as a "gatekeeper" subject to heightened oversight.

That listing showed the Apple-Sonera transaction closing in May 2026, meaning the deal had already been finalized for roughly four months before it became publicly visible in September. It's a pattern that has become almost routine for Apple-watchers: some of the company's most interesting recent acquisitions have come to light not through Cupertino's own disclosures, but through the EU's regulatory paper trail, because Apple's size now means very few of its deals can stay entirely invisible, even when the company would clearly prefer that they did.

Why the Apple Watch Is the Obvious Landing Spot

Apple has spent the better part of a decade turning the Apple Watch from a notification-and-fitness accessory into something closer to a genuine health-monitoring platform. Blood oxygen sensing, ECG readings, fall detection, irregular heart rhythm notifications, temperature sensing for cycle tracking, and increasingly ambitious rumored features around hypertension and sleep apnea detection have all followed the same basic trajectory: take a capability that used to require a clinical device and shrink it down into something that lives on your wrist and runs quietly in the background. Muscle and neural sensing fits that trajectory almost perfectly, and it would address a category of health conditions the Watch currently does very little for.

Continuous, passive monitoring of neuromuscular conditions is the most plausible near-term application. Conditions like Parkinson's disease, essential tremor, multiple sclerosis, and ALS are typically tracked through periodic clinical assessments — a patient visits a specialist every few months, and the doctor evaluates symptoms based on a brief snapshot in time. A wrist-worn sensor capable of picking up subtle changes in muscle activation patterns over weeks and months could, in principle, give both patients and physicians a continuous data stream instead of occasional spot-checks, catching disease progression or medication effectiveness far earlier than an occasional office visit ever could. That's a genuinely compelling accessibility and healthcare pitch, and it lines up with Apple's broader positioning of the Watch as a device that can meaningfully affect people's health outcomes, not just their step counts.

There's also a plausible interaction-design angle. Apple has already shipped a feature called Double Tap on the Apple Watch, which uses the existing accelerometer, gyroscope, and optical heart sensor to detect the subtle wrist motion of tapping your index finger and thumb together, letting users answer calls or dismiss notifications without touching the screen. That feature is a crude, indirect ancestor of what Sonera's technology could enable far more precisely: reading actual muscle activation signals to detect intended gestures, even extremely subtle ones, with much higher accuracy and a much richer vocabulary of possible inputs than an accelerometer can infer. It's not hard to imagine a future Apple Watch, or a future wearable entirely, using magnetic muscle sensing as a general-purpose silent input method, useful for accessibility, for AR and VR interaction (an area where Apple has already invested heavily with Vision Pro), and simply for controlling a device without having to look at it or touch it.

The brain-signal side of Sonera's technology is a far more speculative and distant prospect for a consumer Apple product and it's worth being skeptical about near-term claims of "thought control" showing up in anything Apple ships soon. Reading usable, reliable signals directly from brain activity, even with a fundamentally better sensing approach, is an extraordinarily hard problem, and companies far more singularly focused on it, Neuralink most prominently, though that requires a surgical implant, have taken years to get to even limited real-world deployment. It's much more likely that Apple acquired Sonera primarily for the muscle-sensing capability that already exists in a shipping-adjacent chip, with the brain-sensing research representing a longer-horizon bet that may or may not pay off, rather than a near-term

feature roadmap.

The Bigger Picture

This acquisition also fits a recognisable pattern in how Apple builds new sensing capabilities into its hardware. The company rarely invents entirely new sensor physics in-house; instead, it tends to acquire small teams that have already done the hard, unglamorous work of shrinking a specialised capability down to something approaching commercial viability, then spends years quietly integrating that technology, refining its manufacturing, and building the software and privacy infrastructure around it before it ever appears in a keynote. Blood oxygen sensing, the underlying technology in AirPods' hearing health features, and elements of the Watch's ECG capability all trace back to smaller acquisitions or licensing deals that predated their public debut by years, sometimes with no public link drawn between the acquisition and the eventual feature until well after the fact.

There are real questions worth sitting with here too, separate from the technical excitement. Neural and muscular signal data is about as sensitive as personal data gets, arguably more sensitive than location or even health records in the traditional sense, because it captures something closer to intention and involuntary physiological state rather than just an outcome or a measurement. How that data would be processed, whether it stays on-device in the way Apple has positioned much of its health data processing, and what regulatory frameworks would even apply to consumer-grade neural sensing are all open questions that will matter enormously if this technology does eventually ship in a mainstream product. Apple's public silence on the acquisition means none of that has been addressed yet, and likely won't be until, and unless, the company is ready to talk about an actual product.

Where Sonera Fits Among the Brain Computer Interface Players

It's worth placing Sonera on the broader map of companies chasing brain and neuromuscular interfaces, because the field has quietly become crowded, and the approaches diverge sharply. Neuralink, Elon Musk's company, sits at the most invasive end of the spectrum, implanting electrode arrays directly into the brain via surgery, chasing extremely high-fidelity signal in exchange for real medical risk, a trade-off that makes sense for patients with severe paralysis but is a nonstarter for a mass-market consumer device. Meta's CTRL-Labs technology, inherited through its 2019 acquisition, sits in the middle: a wristband reading electrical signals from motor neurons, non-invasive but still dependent on skin contact and electrical sensing's inherent noisiness.

Companies like Precision Neuroscience have pursued thinner, less invasive implants that sit on the brain's surface rather than penetrating it, another middle-ground approach. Sonera's bet was that magnetic sensing could leapfrog all of these trade-offs at once, no surgery, no required skin contact, and a cleaner signal than electrodes can typically achieve, which is precisely the combination that would make a neural or neuromuscular interface plausible inside a mainstream consumer wearable rather than a medical device or research tool. Whether Sonera had actually closed the gap between that ambition and a manufacturable, battery-efficient chip at Apple Watch scale is exactly the kind of question an acquisition like this is meant to answer, quietly, over the next several product cycles.

For now, what we have is a regulatory filing, a defunct company website, and a trail of technical claims Sonera made about its own S1 chip before it went quiet. It's enough to draw a credible picture of where Apple might be headed, deeper into the body's own electrical and magnetic signals as the next frontier of wearable health tracking, but not enough to say with confidence what that will look like in an actual product, or when. Given Apple's typical timelines for turning an acquired sensing technology into a shipping feature, anything built on Sonera's work is more likely to be a story for 2027 or beyond than for this year's Apple Watch. But the direction is now unmistakable: Apple wants to know not just how fast your heart is beating, but what your muscles, and maybe eventually your mind, are doing too.

Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada #Commonwealth #CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics